Court Opinion

ID: 3207682
Source: CourtListenerOpinion
Date Created: 2016-05-27 21:00:49.243841+00
Date Added: 2024-06-11T07:39:24.864468
License: Public Domain

In the

    United States Court of Appeals
                 For the Seventh Circuit
                    ____________________
No. 15-1502
UNITED STATES OF AMERICA ex rel. JAMES GARBE,
                                           Relator-Appellee,

                                v.

KMART CORPORATION,
                                             Defendant-Appellant.
                    ____________________

         Appeal from the United States District Court for the
                     Southern District of Illinois.
     No. 3:12-cv-00881-NJR-PMF — Nancy J. Rosenstengel, Judge.
                    ____________________

     ARGUED OCTOBER 28, 2015 — DECIDED MAY 27, 2016
                    ____________________

  Before WOOD, Chief Judge, and EASTERBROOK and
HAMILTON, Circuit Judges.
    WOOD, Chief Judge. James Garbe, an experienced pharma-
cist, began working at Kmart pharmacy in Ohio in 2007. One
day, Garbe picked up a personal prescription at a competitor
pharmacy. When he reviewed his receipt, Garbe got a sur-
prise: the competitor pharmacy had charged his Medicare
Part D insurer far less than Kmart ordinarily charged it for the
same prescription. Curious to see whether his discovery was
2                                                    No. 15-1502

a one-off, he started inspecting Kmart’s pharmacy reimburse-
ment claims. His amateur detective work revealed that Kmart
routinely charged customers with insurance—whether public
or private—higher prices than customers who paid out of
pocket. Not all cash customers were charged the same price:
people in Kmart’s “discount programs” paid much less. But
the ensuing investigation revealed that nearly all cash cus-
tomers received the lower “discount program” prices. Mean-
while, those “discount program” sales were ignored when
Kmart calculated its “usual and customary” prices for its ge-
neric drugs for purposes of Medicare reimbursement. Garbe
shared his discovery with the government and filed a qui tam
suit on July 12, 2008. The government has not intervened.
    According to the accepted definition of “usual and cus-
tomary,” Garbe says, Kmart’s “usual and customary” prices
should be based on the prices Kmart charged the majority of
its cash customers, meaning those participating in its generic
drug “discount programs”—not the higher prices it imposed
on a small fraction of those buyers or those with third-party
insurance. After a flurry of motions, the district court granted
partial summary judgment in Garbe’s favor on some issues
and denied it to Kmart on others.
    We accepted an interlocutory appeal from these rulings
under 28 U.S.C. § 1292(b). Before us are several questions: (1)
whether the amendments to 31 U.S.C. § 3729(a)(2) (now
31 U.S.C. § 3729(a)(1)(B)) in the Fraud Enforcement and Re-
covery Act (FERA) apply to all cases “pending on or after June
7, 2008,” or just all claims as of that date; (2) whether Medicare
Part D Pharmacy Benefit Managers and Plan Sponsors are “of-
ficers or employees of the United States” for purposes of the
No. 15-1502                                                  3

FCA; (3) whether Garbe has satisfied the materiality require-
ment under the FCA for his Medicare Part D claims; and (4)
whether Kmart’s “discount” prices were offered to the “gen-
eral public.” We conclude that the district court erred when it
found that the Pharmacy Benefit Managers and Plan Sponsors
are “officers or employees of the United States,” but we oth-
erwise affirm the district court’s rulings.
                               I
                              A
   Garbe’s allegations cover Kmart programs that stretch
back 12 years. In 2004, Kmart introduced a program meant to
compete with online, mail-order pharmacies: the “Kmart
Maintenance Program” (KMP). The KMP offered specified
generic drugs to customers with 90-day prescriptions at a dis-
count price of $15 per prescription.
    Congress added the Part D prescription benefit to Medi-
care, a federally funded health insurance program, in 2006.
Part D allows beneficiaries to opt in to prescription drug ben-
efits by enrolling in a private insurance plan. The program
provides insurance coverage, up to a certain amount, for ben-
eficiaries’ prescription drug costs. Above that amount, benefi-
ciaries are responsible for additional costs up to another set
dollar value, where Part D’s “catastrophic coverage” kicks in.
(This coverage gap is known as the “donut hole.”)
   The Part D program is overseen by the federal Centers for
Medicare and Medicaid Services (CMS). CMS does not ad-
minister the program; instead, it uses Plan Sponsors, which
are private entities that compete for the opportunity to man-
age Part D beneficiaries’ claim submissions and payment pro-
4                                                 No. 15-1502

cesses. Most Plan Sponsors subcontract with Pharmacy Bene-
fit Managers, which are other private entities that work di-
rectly with retail pharmacies to provide prescriptions to
Part D beneficiaries. CMS pays Plan Sponsors fixed monthly
payments according to certain benchmarks. At the end of each
year, it conducts “reconciliation” with the sponsors. The rec-
onciliation process determines, based on Plan Sponsor rec-
ords and a complex subsidy system, whether individual Plan
Sponsors should receive additional funds.
    CMS thus does not directly pay or reimburse any individ-
ual prescriptions through the program. It does control prices,
however, insofar as it requires retail pharmacies to charge
Medicare Part D beneficiaries the “usual and customary”
price, an administratively defined term, for each prescription.
See 42 C.F.R. §§ 423.100, 447.512(b). The district court found
that the “usual and customary” price is generally understood
to mean the “cash price offered to the general public.”
                              B
   Kmart saw the Part D program as an attractive potential
source for new revenue. But Kmart had a problem: the pro-
gram was leading to increased competition among retail
pharmacies, which were developing their own discount ge-
neric-drug programs. This competition, Kmart feared, would
drive down the prices for prescriptions reimbursed by third-
party payers, and therefore revenue.
    In late 2005, as the Part D program was rolling out, Kmart
revamped the KMP. The key reform was a new pricing sys-
tem. According to Kmart internal documents (from which we
take all of the following quotes), Kmart recognized that it was
“financially beneficial to maintain the Usual and Customary
No. 15-1502                                                  5

price higher than reimbursement rates.” Kmart set out to ac-
complish this goal by instituting a policy of setting low “dis-
count” prices for cash customers who signed up for one of its
programs, while charging higher “usual and customary”
prices to non-program cash customers, “to drive as much
profit as possible out of [third-party] programs.” Kmart’s sec-
ond step was simple: it changed the program’s name. In order
to put it at as “long a[s] possible arms length from [Kmart’s]
U&C pricing,” the KMP was relabeled as the “Retail Mainte-
nance Program,” or “RMP.”
     To strengthen Kmart’s “firewall” between RMP and its
“usual and customary” prices, Kmart hired Agelity, a third-
party processor, to administer RMP. According to Garbe’s ev-
idence, however, Agelity’s participation was a sham. In real-
ity, Kmart decided which drugs were in the RMP formulary,
the prices for those drugs, and which customers were eligible
for those prices. In 2008, Kmart expanded RMP to include ad-
ditional drugs and expanded its discount programs to many
30- and 60-day prescriptions. Yet Kmart pharmacists rou-
tinely overrode official program pricing to match competitor
prices. In 2009 Kmart retooled RMP by introducing the “Pre-
scription Savings Club,” under which Kmart officially offered
its low cash prices on 30-, 60-, and 90-day prescriptions. The
programs underwent other modifications along the way. But
according to Garbe, each version of Kmart’s “discount pro-
grams” was the same old wine, in new bottles: Kmart offered
low prices to discount-program cash customers, while sub-
mitting higher “usual and customary” prices for prescriptions
reimbursed by third-party insurers and some non-program
cash customers.
6                                                  No. 15-1502

                               C
    As Garbe sees it, Kmart’s real “usual and customary”
prices were not the high ones paid by non-program cash cus-
tomers or those submitted to third parties for reimbursement,
but the low ones it offered to the cash customers participating
in one of its “discount programs.” These programs, he
charges, were nothing but a sham allowing it to manipulate
its “usual and customary” cash price.
    Garbe retained a pharmaceutical economist, Dr. Joel Hay,
to analyze mountains of reimbursement data. Dr. Hay’s work
revealed that Kmart charged nearly all its cash customers
“discount program” prices. Garbe also hired an auditor, who
testified that, under industry practice and the terms of over
1,000 contracts between Kmart and Medicare Part D Benefit
Managers and Plan Sponsors, Kmart should have based its re-
imbursement requests to the insurance companies handling
Medicare Part D on its “discount program” prices. Dr. Hay’s
examination revealed that Kmart instead used significantly
higher prices when submitting those requests, and was thus
reimbursed at a much higher level.
    At the close of discovery, Kmart filed four motions for par-
tial summary judgment. Relevant to this appeal, it challenged
Garbe’s assertion that Kmart’s “discount programs” were its
actual “usual and customary” prices, and therefore that it
made a false statement in requesting reimbursement based on
allegedly inflated “usual and customary” prices. It also ar-
gued that Garbe’s claims failed for lack of presentment and
materiality on the theory that the government never actually
received or paid any of its reimbursement requests. Related
to its second challenge, it argued that FERA, which amended
the FCA, applied retroactively only to claims pending on or
No. 15-1502                                                     7

after June 7, 2008. (Garbe filed his initial complaint on July 16,
2008.) According to Kmart, this meant that the post-FERA
FCA applied only to a tiny portion of the payments on which
Garbe focused.
    The district court rejected all Kmart’s arguments. It found
as a matter of law that transactions under Kmart’s “discount
programs” represented the “usual and customary” price. It
held that the FERA amendments retroactively covered cases
pending on June 7, 2008, and therefore they applied to all of
transactions Garbe had identified. It also found that Garbe’s
evidence raised at least a genuine dispute of material fact
about Kmart’s liability under 31 U.S.C. § 3729.
     After some adjustments in response to its motion for re-
consideration, Kmart asked the district court to certify its
summary judgment order for interlocutory appeal under
28 U.S.C. § 1292(b). The court obliged and identified three
pivotal issues: (1) whether the retroactivity provision relevant
to 31 U.S.C. § 3729(a)(2) [now 31 U.S.C. § 3729(a)(1)(B)] ap-
plies to all cases “pending on or after June 7, 2008,” as opposed
to all payments after that date; (2) whether Medicare Part D
Pharmacy Benefit Managers and Plan Sponsors are “officers
or employees of the United States” for purposes of the FCA;
and (3) whether Garbe satisfied the FCA materiality require-
ment for his Medicare Part D claims. We granted Kmart’s pe-
tition and added the question whether the district court cor-
rectly identified the “usual and customary” price.
                               II
   We consider de novo the district court’s rulings on partial
summary judgment, construing the facts in the light most fa-
vorable to the non-moving party—in this case, Garbe. Jaburek
8                                                   No. 15-1502

v. Foxx, 813 F.3d 626, 630 (7th Cir. 2016). Summary judgment
is appropriate when there is no dispute of material fact, and
the moving party is entitled to judgment as a matter of law.
FED. R. CIV. P. 56(a).
                               A
    Kmart opens with its retroactivity argument, which if suc-
cessful would knock out almost all of Garbe’s case. It urges
that § 3729(a)(1)(B) of the 2009 FERA Amendments covers
only requests for reimbursement that were pending on or af-
ter June 7, 2008 (four days before Garbe filed his suit). Garbe
reads the statute more expansively, to cover all cases pending
on or after that date. Kmart also argues that it cannot be liable
under the False Claims Act because (it contends) Garbe has
failed to present evidence that (1) he properly presented the
pre-FERA False Claims Act to the government and (2) the
false claims were “material.”
                               1
    Since 2009, the FCA has said that “any person who ...
(1)(A) knowingly presents, or causes to be presented, a false
or fraudulent claim for payment or approval” or “(B) know-
ingly makes, uses, or causes to be made or used, a false record
or statement material to a false or fraudulent claim” is liable
under the False Claims Act. 31 U.S.C. § 3729(a)(1) (2009). But
the section did not always read that way. Before the enactment
of FERA, 31 U.S.C. § 3729, it provided for liability for “[a]ny
person who ... (1) knowingly presents, or causes to be pre-
sented, to an officer or employee of the United States Government
or a member of the Armed Forces of the United States a false or
fraudulent claim for payment or approval;” or “(2) knowingly
makes, uses, or causes to be made or used, a false record or
No. 15-1502                                                   9

statement to get a false or fraudulent claim paid or approved by
the Government.” Id. § 3729(a) (1994) (emphasis added).
    The change occurred because of a Supreme Court deci-
sion. In 2008, the Court held that FCA § 3729(a)(1) requires a
defendant’s direct presentment of the false claim to an officer
or employee of the government. Allison Engine Co. v. United
States ex rel. Sanders, 553 U.S. 662, 668 (2008). The Court fur-
ther held that for liability under § 3729(a)(2) to attach, there
had to be proof that the defendant had a specific intent to de-
fraud the government. Id.
    Congress responded the next year by enacting FERA.
FERA excised the language requiring that the claim be pre-
sented “to an officer or employee of the United States Govern-
ment or a member of the Armed Forces of the United States.”
It also struck from § 3729(a)(2) the words “to get a false or
fraudulent claim paid or approved by the Government,”
which the Supreme Court had interpreted to require a specific
intent to defraud the government. See Allison Engine, 553 U.S.
at 668–69. The revised law imposed only the less onerous re-
quirement that the “false record or statement” be “material to
a false or fraudulent claim.”
    FERA also clarified the statutory definitions for “claim”
and “material.” It defined “claim” to mean, in relevant part,
“any request or demand ... for money or property, that ... is
made to a contractor, grantee, or other recipient, if the money
or property is to be spent or used on the Government’s behalf
or to advance a Government program or interest” and to
which the government either “provides or has provided any
portion of the money or property” or “will reimburse such
contractor, grantee, or other recipient for any portion of the
money or property.” 31 U.S.C. § 3729(b)(2) (2009). The new
10                                                 No. 15-1502

language underscored Congress’s intent that FCA liability at-
tach to any false claim made to an entity implementing a pro-
gram with government funds, regardless of whether that en-
tity was public or private. FERA defines “material” to mean
“having the natural tendency to influence, or be capable of
influencing, the payment or receipt of money or property.” Id.
§ 3729(b)(4). Notably missing from this definition is any re-
quirement that the false statement or record be material to the
government program.
    Whether we call the changes made by FERA clarifications
or changes, the end result is clear: as amended, the FCA con-
tains no presentment requirement. For any transactions to
which FERA applies, Garbe is thus not required to show that
any statement or record was delivered to any government em-
ployee, official, or entity. FCA liability attaches to any false
claim to any entity—public or private—implementing a gov-
ernment program or a program using government funds.
                               2
    Kmart’s materiality arguments are similarly mistaken.
Kmart contends that Garbe has not raised a genuine issue of
fact on materiality because he offered no evidence that the al-
leged overcharges were capable of affecting the government’s
payment decision. But FERA’s materiality rule requires only
that the false record or statement influence the “payment or
receipt of money or property”—no government decision is re-
quired. 31 U.S.C. § 3729(b)(4) (emphasis added). Garbe is re-
quired to show only that Kmart’s allegedly false claims were
material to Kmart’s receipt of more money than it should have
gotten. In other words, Kmart’s misstatements had to be “ca-
pable of influencing[] the decisionmaking body to which
[they were] addressed.” Neder v. United States, 527 U.S. 1, 16
No. 15-1502                                                    11

(1999) (noting, for tax fraud statute with same materiality def-
inition, that numerous courts have found “any failure to re-
port income is material”). Dr. Hay’s report shows that, to the
extent Kmart made false claims, they were material: those
claims were the basis of the federal monies Kmart received.
    Kmart argues that there must be a “causal chain” between
a false claim and a CMS payment, but it offers no support for
such a rule. FERA had the effect of bringing within the FCA’s
ambit false claims to intermediaries or other private entities
that either implement government programs or use govern-
ment funds. See 31 U.S.C. § 3729(b)(2) (2009). There is little
doubt that much of the money paid to Kmart under Medicare
Part D came from government coffers. See, e.g., 2014 Annual
Report of the Boards of Trustees of the Federal Hospital Insurance
and Federal Supplementary Medical Insurance Trust Funds 103
(funds from U.S. Treasury made up 73.1% of total revenue dis-
bursed by Medicare Part D trust fund in fiscal year 2013).
Garbe is not required to trace the movement of currency from
the U.S. Treasury through the Medicare Part D funding struc-
ture; Kmart’s argument in this respect is just presentment in
materiality clothing. Kmart is not entitled to summary judg-
ment for lack of either presentment or materiality for any
claims to which FERA applies.
                                3
    Having found that Garbe’s claims satisfy the post-FERA
version of the FCA, we now consider whether that version ap-
plies to them. In FERA § 4(f), Congress said that the amend-
ments were effective “as if [subsection (a)(1)(B) had been] en-
acted on June 7, 2008,” and that they “apply to all claims un-
der the False Claims Act that are pending on or after that
date.” 123 Stat. at 1625 (not codified). Kmart argues that the
12                                                     No. 15-1502

“claims” to which this refers are demands for payment, not
FCA cases. Garbe takes the broader view.
    We have held before that the word “claims” in § 4(f)(1) re-
fers to cases, not to individual requests for payment. See
United States ex rel. Yannacopoulos v. Gen. Dynamics, 652 F.3d
818, 822 n.2 (7th Cir. 2011) (“[S]ection 3729(a)(1)(B) ... applies
to cases, such as this, that were pending on or after June 7,
2008.”); United States v. Sanford-Brown, Ltd., 788 F.3d 696, 701
n.1 (7th Cir. 2015) (same); Thulin v. Shopko Stores Operating Co.,
LLC, 771 F.3d 994, 998 (7th Cir. 2014) (same). The majority of
our sister circuits take the same position. See Sanders v. Allison
Engine Co., 703 F.3d 930, 942 (6th Cir. 2012) (holding that
“‘claim’ in § 4(f)(1) refers to a civil action or case”); United
States ex rel. Kirk v. Schindler Elevator Corp., 601 F.3d 94, 113 (2d
Cir. 2010) (holding § 3729(a)(1)(B) retroactive as to lawsuits),
rev’d on other grounds, 563 U.S. 401 (2011); United States ex rel.
Rigsby v. State Farm Fire & Cas. Co., 794 F.3d 457, 465 (5th Cir.
2015) (same).
    This is the interpretation that best reflects the text and
structure of the statute. Construing “claims” to mean “re-
quests for payment” makes no sense. There is no such thing
as a request or demand for payment under the False Claims
Act. Rather, a claim “under the [FCA]” is a legal action by the
government or a relator to recover fraudulently obtained
funds. See 123 Stat. at 1625; Sanders, 703 F.3d at 938.
    Construing the FERA amendments as retroactive only for
requests or demands for payment is also in tension with Con-
gress’s stated goal of changing Allison Engine’s interpretation
of § 3729(a). Congress specified that the FERA provision cod-
ified as § 3729(a)(1)(B) should be applied “as if ... enacted on
June 7, 2008.” 123 Stat. at 1625. That date is two days before
No. 15-1502                                                   13

June 9, 2008, the date when the Supreme Court handed down
Allison Engine, and a Saturday (June 9, 2008, was a Monday).
It seems no accident that Congress picked Saturday, June 7,
2008, as the date of retroactivity: by choosing that date, it
could eliminate the approach taken in Allison Engine without
reopening judgments that were already final when Allison En-
gine was decided.
    Interpreting § 4(f)(1)’s “claims” to mean “cases” accom-
plishes this goal. Interpreting it as “any request or demand,
whether under a contract or otherwise, for money or prop-
erty” does not. Kmart offers no reason why, under its theory,
Congress would have chosen June 7, 2008, for the effective
date. Worse, Kmart’s reading would render meaningless what
is arguably § 4(f)(1)’s most important element—the date of
retroactivity—and thus violate the “cardinal principle of stat-
utory construction that a statute ought, upon the whole, to be
so construed that, if it can be prevented, no clause, sentence,
or word shall be superfluous, void, or insignificant.” See TRW
Inc. v. Andrews, 534 U.S. 19, 31 (2001) (internal quotation
marks omitted); Stone v. I.N.S., 514 U.S. 386, 397 (1995)
(“When Congress acts to amend a statute, we presume it in-
tends its amendment to have real and substantial effect.”).
    Kmart argues that because the FCA provides a statutory
definition of “claim,” that definition should control. It is true
that “[s]tatutory definitions control the meaning of statutory
words ... in the usual case.” Burgess v. United States, 553 U.S.
124, 129 (2008). And § 3729(b)(2)(A) defines “claim” as “any
request or demand ... for money or property.” Kmart argues
that the retroactivity provision therefore applies only to de-
mands for payment that were pending on June 7, 2008, not law-
suits. But this argument does not survive closer examination:
14                                                     No. 15-1502

section 3729(b) specifies that the statutory definition of
“claim” is only “for purposes of this section.” Because § 4(f)
of FERA is not mentioned in § 3729(b), the latter section dic-
tates that its definition does not apply to § 4(f).
    Kmart argues that its interpretation is reinforced by other
parts of the FERA. It is true that “[c]ontext, not just literal text,
will often lead a court to Congress’ intent in respect to a par-
ticular statute.” United States v. Webber, 536 F.3d 584, 593 (7th
Cir. 2008). And § 4(f)(2)—the adjacent provision—specifies
that certain other amendments to the FCA would “apply to
cases pending on the date of enactment.” 123 Stat. at 1625 (em-
phasis added). This juxtaposition, Kmart says, implies that
Congress knew how to refer to “cases” when it intended to,
but chose not to do so in § 3729(a)(1)(B).
    But the presumption that “disparate inclusion or exclu-
sion” is purposeful is weakened when, as here, the provisions
were not joined together or considered simultaneously. Sand-
ers, 703 F.3d at 937; cf. Lindh v. Murphy, 521 U.S. 320, 330 (1997)
(“[N]egative implications raised by disparate provisions are
strongest when the portions of a statute treated differently
had already been joined together and were being considered
simultaneously when the language raising the implication
was inserted.”). Sections 4(f)(1) and 4(f)(2) were drafted by
different chambers of Congress, at different times. See Sand-
ers, 703 F.3d at 936–37; Matthew Titolo, Retroactivity and the
Fraud Enforcement and Recovery Act of 2009, 86 IND. L.J. 257, 298
(2011); S. 386, 111th Cong. § 4(b) (as reported in Senate, March
5, 2009); S. 386, 111th Cong. § 4(f) (House engrossed amend-
ment, May 6, 2009).
    Moreover, the “presumption that identical words used in
different parts of the same act are intended to have the same
No. 15-1502                                                     15

meaning ... is not rigid and readily yields whenever there is
such variation in the connection in which the words are used
as reasonably to warrant the conclusion that they were em-
ployed in different parts of the act with different intent.” Gen.
Dynamics Land Sys., Inc. v. Cline, 540 U.S. 581, 595 (2004) (quot-
ing Atl. Cleaners & Dyers v. United States, 286 U.S. 427, 433
(1932)). The presumption is especially weak when the word
“has several commonly understood meanings.” Cline, 540
U.S. at 595–96. “Claim” is just such a word.
    Congress’s free use of “claim” (along with “action”) to
mean “civil action” throughout the FCA further supports the
argument that § 4(f)(1) was not meant to incorporate the def-
inition in § 3729(b)(2)(A). See, e.g., 31 U.S.C. §§ 3730(c)(5) (the
government “may elect to pursue its claim through any alter-
nate remedy available”); 3731(c) (repeated references to the
government’s “claims” in describing procedure for interven-
tion in FCA lawsuit); 3732(b) (referring to “[c]laims under
state law” in conveying district courts’ jurisdiction over “any
action brought under the laws of any State”); see also Sanders,
703 F.3d at 939 (noting same in discussing issue).
     Finally, Kmart maintains that three other courts of ap-
peals, albeit in footnotes, have agreed with it. See Hopper v.
Solvay Pharm., Inc., 588 F.3d 1318 n.1 (11th Cir. 2009) (inter-
preting “claim” in § 4(f)(1) to mean “any request or demand
... for money or property”); Gonzalez v. Fresenius Med. Care N.
Am., 689 F.3d 470, 475 n.4 (5th Cir. 2012) (noting approvingly
that the district court held that FERA did not apply to conduct
occurring before its enactment); United States ex rel. Cafasso v.
Gen. Dynamics C4 Sys., Inc., 637 F.3d 1047, 1051 n.1 (9th Cir.
2011) (citing Hopper in holding that FERA did not apply to
16                                                  No. 15-1502

case). None of these cases, however, addressed the question
with any analysis, and so they give us little pause.
    All things considered, we have no trouble concluding that
the word “claims” does not mean “request[s] or demand[s]
for ... money or property.” It means “cases,” and thus § 4(f)(1)
applies to FCA cases pending on or after June 7, 2008.
                               B
    With the broader point established, the practical impact of
Kmart’s next point, which relates to its liability under the pre-
FERA version of the Act, is greatly diminished. This issue is
relevant only to the extent that any of the transactions about
which Garbe is complaining are not covered by the amended
version of § 3729(a)(1)(B). (Whether there are any such trans-
actions is a matter yet to be resolved by the district court.) As
we have noted, none of Garbe’s allegations involve false
claims submitted directly to the government. Kmart contends
that Garbe may rely on the former § 3729(a)(1) (1994) only if
§ 3729(a)(1)(A) is construed to be retroactive “clarifying” leg-
islation rather than a “substantive” amendment.
    Although retroactive application of statutes “is not fa-
vored,” a statute will be construed “to have retroactive effect”
where its “language requires this result.” Republic of Austria v.
Altmann, 541 U.S. 677, 692 (2004) (citations omitted). In decid-
ing whether an amendment is clarifying rather than substan-
tive, we consider “[1] whether the enacting body declared that
it was clarifying a prior enactment; [2] whether a conflict or
ambiguity existed prior to the amendment; and [3] whether
the amendment is consistent with a reasonable interpretation
of the prior enactment and its legislative history.” Middleton v.
No. 15-1502                                                       17

City of Chicago, 578 F.3d 655, 663–64 (7th Cir. 2009). The Su-
preme Court has emphasized the importance of the first and
second factors. See, e.g., Cherokee Nation of Oklahoma v. Leavitt,
543 U.S. 631, 646–47 (2005) (statute not clarifying where ear-
lier “statutes ... were not ambiguous” despite legislative his-
tory evincing intent to clarify); Rivers v. Roadway Exp., Inc., 511
U.S. 298, 307 (1994) (requiring “clear expression of congres-
sional intent” for retroactive effect despite evidence that Con-
gress intended to disapprove a judicial interpretation).
    There are several problems with interpreting
§ 3729(a)(1)(A) to be retroactive to a time before the stated ef-
fective date. It is a stretch, first, to say that the earlier version
of the law was ambiguous. Presentment of a claim “for pay-
ment or approval” to “an officer or employee of the United
States Government or a member of the Armed Forces of the
United States” was an important part of § 3729(a)(1). The
sounder conclusion, we believe, is that § 3729(a)(1)(A) follows
the normal presumption that statutes do not have retroactive
effect.
    Garbe argues that even if the amendments are not retroac-
tive and the presentment requirement applies to some claims,
the intermediaries that actually reimbursed Kmart’s allegedly
fraudulent claims should be considered to be “officer[s] or
employee[s] of the United States Government” under
§ 3729(a)(1) (1994). He points to Bodimetric Health Services Inc.
v. Aetna Life & Casualty, 903 F.2d 480, 488 (7th Cir. 1990), which
found that certain intermediaries’ acts were covered by an ex-
clusive remedy prescribed by the Medicare Act because those
intermediaries performed a “public function” under the Act.
Id. But Bodimetric did not find that the intermediaries stood in
for “the government” for the purpose of the exclusive remedy
18                                                   No. 15-1502

provision, let alone for FCA presentment. Id. In addition, find-
ing that they did so would be inconsistent with our holding
in Juhong v. Boeing Co., 792 F.3d 805, 808–10 (7th Cir. 2015) (ad-
dressing who is an officer of the United States for purposes of
removal under 28 U.S.C. § 1442). Finally, deeming any con-
tractor implementing a government program to be “the gov-
ernment” would functionally eliminate the presentment re-
quirement. To the extent Garbe’s suit covers pre-FERA trans-
actions that do not rely on § 3729(a)(1)(B), he cannot rely upon
§ 3729(a)(1)(A).
                                C
   Finally, we address Kmart’s contention that the term “gen-
eral public,” as found in the definition of “usual and custom-
ary” pricing, excludes persons participating in its “discount
programs.”
    Unless state regulations provide otherwise, the “usual and
customary” price is defined as the “cash price offered to the
general public.” Garbe alleges that Kmart’s actual “usual and
customary” prices are the prices it charges through several ge-
neric-drug discount programs. If he is correct, Kmart misrep-
resented its “usual and customary” prices by charging Medi-
care Part D participants far in excess of those prices—some-
times as much as 30 times more. Kmart argues that because
the participants in its discount programs were not the “gen-
eral public,” those prices were not its “usual and customary”
charges. Although the district court decided that the defini-
tion of “usual and customary” raised a question of law, it
nonetheless took expert evidence on the industry definition of
the term. It resolved the meaning of “general public” without
taking evidence.
No. 15-1502                                                   19

                               1
    Kmart argues that the ordinary meaning of “general pub-
lic” excludes customers who join a discount program. It
points to two definitions of “general public” from online dic-
tionaries: first, “ordinary people in society, rather than people
who are considered to be important or who belong to a par-
ticular group,” Macmillan Dictionary Online, http://www.mac-
millandictionary.com/dictionary/british/the-general-public
(visited May 18, 2016); and second, “ordinary people, espe-
cially all the people who are not members of a particular or-
ganization or who do not have any special type of
knowledge.” Cambridge Dictionaries Online, http://diction-
ary.cambridge.org/us/dictionary/english/the-general-pub-
lic?q=general+public (visited May 18, 2016). It argues that be-
cause members of its discount programs “belong to a partic-
ular group” or “organization” that represents a subset of its
customer base, they are not members of the general public
and the price they were charged is not the usual and custom-
ary price.
    Saying that someone is a member of a “particular” organ-
ization, however, does not make it so. We are given no reason
to think that there was any meaningful selectivity for the peo-
ple who joined Kmart’s programs, and thus that they could be
distinguished in any way from the “general public.” Few of
Kmart’s customers would consider themselves as “be-
long[ing] to a particular group” or “members of a particular
organization” just because they accepted Kmart’s offer of a
discount. Even if the prices were offered only to members of
its “discount programs”—and it is disputed whether this was
the case—the programs themselves were offered to the gen-
20                                                 No. 15-1502

eral public. Kmart’s programs typically offered its “dis-
counts” in return for nothing more than assent, demographic
data the pharmacy already needed to fill a prescription, and a
nominal fee.
    The evidence submitted shows that the barriers to joining
the Kmart “programs” were almost nonexistent, to the extent
they were enforced at all. Cash customers walking into Kmart
do not cease to be members of the general public the minute
they are offered—or pushed into—“membership” in Kmart’s
“discount program.” The program’s most robust version al-
lowed customers to obtain its “benefits” immediately for ten
dollars. (For those people, the program fee is part of the cash
price: for example, if the fee was $10 and the program drug
price was $15, the customer paid $25 for her first prescription.
For people who fill more than one prescription, the $10 fee
would need to be allocated in some sensible way.) Garbe’s ex-
pert indicated that most of Kmart’s cash customers received
its “discount” prices.
   Our reading of “general public” is consistent with the reg-
ulatory structure that gave rise to the “usual and customary”
price term. Under 42 C.F.R. § 423.100, the “[u]sual and cus-
tomary (U&C) price means the price that an out-of-network
pharmacy or a physician’s office charges a customer who does
not have any form of prescription drug coverage for a covered
Part D drug.” The term is included in state regulations, plans,
and contracts related to Medicare Part D because the Medi-
care and Medicaid regulations demand that it be. Id.
§ 447.512(b). Its meaning in many state regulations, plans, and
contracts is lifted from the federal regulations without signif-
icant modification.
No. 15-1502                                                    21

    Medicare, Medicaid, and their corresponding regulations
mandate that state plans ensure that “payments for services
be consistent with efficiency, economy, and quality of care.”
Id. § 447.200 (citing 42 U.S.C. § 1396a(a)(30)). Under 42 C.F.R.
§ 50.503, “[i]t is the policy of the Secretary that program funds
which are utilized for the acquisition of drugs be expended in
the most economical manner feasible.” The Medicare regula-
tions mandate that payments for drugs under the program
must not exceed “the lower of the[] (1) [Estimated Acquisition
Cost] plus reasonable dispensing fees established by the
agency; or (2) Providers’ usual and customary charges to the
general public.” Id. § 447.512(b). The Estimated Acquisition
Cost is “the agency’s best estimate of the price generally and
currently paid by providers for a drug marketed or sold by a
particular manufacturer or labeler in the package size of drug
most frequently purchased by providers.” Id. § 447.502.
     Taken together, “[t]he purpose of these regulations is clear:
state agencies are not to pay more for prescribed drugs than
the prevailing retail market price.” United States v. Bruno’s,
Inc., 54 F. Supp. 2d 1252, 1257 (M.D. Ala. 1999) (interpreting
42 C.F.R. § 447.512(b), then numbered 42 C.F.R. § 447.331(b)).
Regulations related to “usual and customary” price should be
read to ensure that where the pharmacy regularly offers a
price to its cash purchasers of a particular drug, Medicare Part
D receives the benefit of that deal. See generally Arkansas
Pharmacists Ass’n v. Harris, 627 F.2d 867, 869 n.4 (8th Cir. 1980)
(noting that “[t]he [Maximum Allowable Cost],” relevant only
if lower than the usual and customary price, “is basically the
lowest price at which a drug is widely and consistently avail-
able.”).
22                                                    No. 15-1502

    An agency’s interpretation of its own regulation is given
“controlling weight unless it is plainly erroneous or incon-
sistent with the regulation.” Thomas Jefferson Univ. v. Shalala,
512 U.S. 504, 512 (1994) (quoting Bowles v. Seminole Rock &
Sand Co., 325 U.S. 410, 414 (1945)); cf. United Student Aid Funds,
Inc. v. Bible, No. 15-861, cert. denied, May 16, 2016 (raising ques-
tion whether Auer v. Robbins, 519 U.S. 452 (1997), should be
overruled). The CMS Manual has long noted that “where a
pharmacy offers a lower price to its customers throughout a
benefit year” the lower price is considered the “usual and cus-
tomary” price rather than “a one-time ‘lower cash’ price,”
even where the cash purchaser uses a discount card. CENTERS
FOR MEDICARE & MEDICAID SERVS., Chapter 14 – Coordination of
Benefits, in MEDICARE PRESCRIPTION DRUG BENEFIT MANUAL 19
n.1 (2006), https://perma.cc/MW6A-H4P6. Kmart offered its
“discount” prices to customers continuously, throughout
multiple benefit years.
    Allowing Kmart to insulate high “usual and customary”
prices by artificially dividing its customer base would under-
mine a central purpose of the statutory and regulatory struc-
ture. The “usual and customary” price requirement should
not be frustrated by so flimsy a device as Kmart’s “discount
programs.” Because Kmart offered the terms of its “discount
programs” to the general public and made them the lowest
prices for which its drugs were widely and consistently avail-
able, the Kmart “discount” prices at issue represented the
“usual and customary” charges for the drugs.
                                 2
   Kmart argues that even if it is not entitled to summary
judgment on whether its discount prices were its “usual and
customary” charges, the issue is one of fact and appropriate
No. 15-1502                                                    23

for a jury. But the interpretation of contractual and regulatory
terms is generally a question of law. See Hanover Ins. Co. v. N.
Bldg. Co., 751 F.3d 788, 791 (7th Cir. 2014) (“[C]ontract inter-
pretation is a question of law.”); Urso v. United States, 72 F.3d
59, 60 (7th Cir. 1995) (“[T]he meaning of a regulation is a ques-
tion of law for the court, not of fact for the jury.”). No special
consideration prevents this question from being resolved at
summary judgment.
                               III
    FERA § 4(f) made 31 U.S.C. § 3729(a)(1)(B) (2009) retroac-
tive with respect to cases, not just requests for payment. The
current version of § 3729(a)(1)(B) therefore applies to (almost)
all of Garbe’s claims. Because Garbe has presented evidence
sufficient to create a genuine dispute of material fact, his
§ 3729(a)(1)(B) claims survive summary judgment. FERA was
not, however, mere clarifying legislation with regard to the
pre-FERA § 3729(a)(1). Thus, if and to the extent any of
Garbe’s claims rely on the earlier law, they fail for lack of pre-
sentment. Finally, participants in Kmart’s “discount pro-
grams” qualify as the “general public” for the purpose of de-
termining the relevant “usual and customary” prices. We
therefore AFFIRM in part and REVERSE in part, and REMAND for
proceedings consistent with this opinion.